Use of s1pr1 selective agonist sar247799 in the manufacture of a medicament for treating a neuromyelitis optica spectrum disorder

CN122097375APending Publication Date: 2026-05-29SHAANXI NORMAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SHAANXI NORMAL UNIV
Filing Date
2026-04-28
Publication Date
2026-05-29

AI Technical Summary

Technical Problem

Existing drugs cannot precisely target the S1PR1 pathway in astrocytes, resulting in a lack of specificity in NMOSD treatment and the risk of worsening the condition. Current treatment methods cannot effectively alleviate the core pathological damage of NMOSD.

Method used

Using the S1PR1 selective agonist SAR247799, astrocyte signaling was activated by upregulating S1PR1 expression in astrocytes, inhibiting AQP4-IgG and complement-induced cell damage, and an injectable formulation was prepared for intraperitoneal injection.

Benefits of technology

It significantly reduced the loss of AQP4, GFAP, and ALDH1L1 in the brains of NMOSD model mice, protected astrocytes, alleviated NMOSD pathological damage, and provided a novel therapeutic strategy targeting astrocytes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122097375A_ABST
    Figure CN122097375A_ABST
Patent Text Reader

Abstract

The application discloses application of an S1PR1 selective agonist SAR247799 in preparation of a drug for treating neuromyelitis optica spectrum disorders. The SAR247799 can up-regulate S1PR1 expression of astrocytes, activate an S1PR1 signal path of the astrocytes, inhibit AQP4-IgG and complement-mediated damage of the astrocytes, reduce loss of AQP4, GFAP and ALDH1L1 in a lesion area of brain tissue of a neuromyelitis optica spectrum disorder model mouse, and relieve pathological damage of the neuromyelitis optica spectrum disorder model. In-vivo and in-vitro experiments prove that the SAR247799 can effectively inhibit AQP4-IgG and complement-dependent cytotoxicity effects and promote survival of the astrocytes. The application provides a novel, efficient and specific targeted drug for clinical treatment of the neuromyelitis optica spectrum disorder.
Need to check novelty before this filing date? Find Prior Art